November 27, 2023 – Page 2

Daktronics, Inc. to Release Second Quarter Fiscal 2024 Financial Results

Written by Customer Service on November 27, 2023. Posted in Public Companies.

BROOKINGS, S.D., Nov. 27, 2023 (GLOBE NEWSWIRE) — Daktronics, Inc. (NASDAQ-DAKT), announced today it will release its second quarter fiscal 2024 financial results on Tuesday, December 5, 2023 before the market opens. The Company will host a conference call and webcast for all interested parties at 10:00 AM CT that day. Reece A. Kurtenbach, Chief Executive Officer and Sheila M. Anderson, Chief Financial Officer, will host the conference call, which will contain forward-looking statements and other material information. The conference call may be accessed by a dial-in number or via the Internet as follows: Tuesday, December 5, 2023 at 10:00 AM CT Webcast: https://edge.media-server.com/mmc/p/gmk3f5pe Participant Registration: https://register.vevent.com/register/BI0fdd34523c844d09bf2e5f2d17c642bb About Daktronics Daktronics has...

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on November 27, 2023. Posted in Public Companies.

FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved an equity award under Ocuphire’s 2021 Inducement Plan, as a material inducement to Joseph K. Schachle, the Company’s newly appointed Chief Operating Officer, in connection with his employment with the Company effective on November 27, 2023. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with his entering into employment...

Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

Written by Customer Service on November 27, 2023. Posted in Public Companies.

Clinical study randomizing up to 1,200 patients designed to help change guidelines in treating intermediate-risk Pulmonary Embolism (PE) patients globally Image 1 PEERLESS II RCT Comparing Mechanical Thrombectomy to Conservative Medical Management IRVINE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the first patient enrollment in the PEERLESS II study. This prospective, global, multi-center randomized controlled trial (“RCT”) compares the outcomes of intermediate-risk acute pulmonary embolism (“PE”) patients treated with the FlowTriever® System against those treated with traditional anticoagulation therapy alone. The first patient was enrolled...

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Written by Customer Service on November 27, 2023. Posted in Public Companies.

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024 Reiterating year-end 2023 cash and investments of $400 to $410 million and cash runway through year-end 2026 SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclusive license agreement for Centessa Pharmaceuticals’ (NASDAQ: CNTA) blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases. Anaptys anticipates filing...

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

Written by Customer Service on November 27, 2023. Posted in Public Companies.

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio...

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

Written by Customer Service on November 27, 2023. Posted in Public Companies.

HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th at 5:05 pm ET. A webcast of the presentation will be available on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways...

Earth Alive Announces 34% Year over Year Sales Increase During its Third Quarter

Written by Customer Service on November 27, 2023. Posted in Earnings Releases And Operating Results.

MONTRÉAL, Nov. 27, 2023 (GLOBE NEWSWIRE) — Earth Alive Clean Technologies Inc. (TSXV: EAC – “Earth Alive” or the “Company”), a leader in the development, production and distribution of technological solutions that allow the industry to move from the chemical era to the organic era, announces today its financial results for the quarter ended September 30, 2023. Business Highlights 34% revenue increase Year over Year for the three months period ended September 30, 2023. Important sales of Soil ActivatorTM to a new customer in western Canada, with recurrent orders expected. Efforts to continue implementation of our microbial dust suppressant ea1TM by reinforcing the sales team in Québec First commercial shipment of Soil Activator in Europe during the Quarter. Third Quarter 2023 financial highlights Sales for the second quarter...

Locafy Reports Fiscal First Quarter 2024 Results

Written by Customer Service on November 27, 2023. Posted in Earnings Releases And Operating Results.

Fiscal First Quarter 2024 Highlighted by Strategic Partnerships, Maintained Gross Margin of 81%, and 53% Year-Over-Year Cost of Sales Decrease Continued Cost-Efficiency Initiatives Help Drive Locafy Closer to Profitability; Milestone Expected Early in Calendar-Year 2024 PERTH, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) — Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in local search engine marketing, today reported financial results for the 2024 fiscal first quarter ended September 30, 2023. All financial results are reported in Australian Dollars (AUD). Recent Operational Highlights Announced an enterprise partnership with Method, an Australian digital marketing agency with local-scale expertise. Method has been using Locafy’s products...

Zscaler Reports First Quarter Fiscal 2024 Financial Results

Written by Customer Service on November 27, 2023. Posted in Earnings Releases And Operating Results.

First Quarter Highlights Revenue grows 40% year-over-year to $496.7 million Calculated billings grows 34% year-over-year to $456.6 million Deferred revenue grows 39% year-over-year to $1,399.5 million GAAP net loss of $33.5 million compared to GAAP net loss of $68.2 million on a year-over-year basis Non-GAAP net income of $106.5 million compared to non-GAAP net income of $44.0 million on a year-over-year basis SAN JOSE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) — Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its first quarter of fiscal year 2024, ended October 31, 2023. “We had a strong start to our fiscal year with all key metrics coming above our guidance. We are enabling enterprises to move forward with their key transformative initiatives – Zero Trust and AI – which...

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Written by Customer Service on November 27, 2023. Posted in Public Companies.

— Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise — — Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial Manufacturing Strategy as Lead PCV Candidate, VAX-24, Advances into Phase 3 — SAN CARLOS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) today announced that Vaxcyte has exercised its option and entered into a manufacturing rights agreement with Sutro to obtain control over the development and manufacture of cell-free extract, a key component of Vaxcyte’s pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-24 and...

Day: November 27, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice